Cabergoline 0.5 MG Oral Tablet — RxCUI 199703
RxNorm drug concept · Semantic clinical drug
RxCUI 199703
Semantic clinical drug · SCD
● Current RxNorm concept 12 FDA products
12 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI199703
Official nameCabergoline 0.5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped12
Package NDCs mapped12
Reported Medicaid activity (SDUD)70,969 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Cabergoline: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Prolactin is a hormone your pituitary gland makes — it's best known for triggering breast milk production. When prolactin is too high outside of pregnancy or breastfeeding, it can...
- What exactly is cabergoline treating — what does 'high prolactin' mean for me?
- Prolactin levels can start to drop within a few weeks of starting cabergoline, though it may take longer for symptoms like irregular periods to fully improve. Your dose will be adj...
- How soon will I feel better, and how long will I need to take it?
🕸️ Concept Web — How Cabergoline 0.5 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Cabergoline 0.5 MG Oral Tablet
RxCUI 199703 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Cabergoline
47579IN
-
Cabergoline
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Cabergoline Oral Tablet
371178SCDF -
Cabergoline Oral Product
1164946SCDG -
Cabergoline Pill
1164947SCDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Cabergoline Oral Tablet
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Cabergoline 0.5 MG
315505SCDC
-
Cabergoline 0.5 MG
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Cabergoline 0.5 MG
SCDC · 315505 -
Cabergoline Oral Tablet
SCDF · 371178 -
Cabergoline Oral Product
SCDG · 1164946 -
Cabergoline Pill
SCDG · 1164947
📦 FDA Products & Package NDCs
12 products · 12 package NDCs
12 package NDCs map to RxCUI 199703 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00093-5420-88 | 1 BOTTLE in 1 CARTON (0093-5420-88) / 8 TABLET in 1 BOTTLE | Cabergoline | Teva Pharmaceuticals USA, Inc. | 2007-03-07 |
| 23155-0823-73 | 8 TABLET in 1 BOTTLE (23155-823-73) | Cabergoline | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 2022-06-15 |
| 50090-3157-00 | 1 BOTTLE in 1 CARTON (50090-3157-0) / 8 TABLET in 1 BOTTLE | Cabergoline | A-S Medication Solutions | 2017-10-06 |
| 50090-5834-00 | 8 TABLET in 1 BOTTLE (50090-5834-0) | Cabergoline | A-S Medication Solutions | 2021-10-27 |
| 50090-6596-00 | 8 TABLET in 1 BOTTLE (50090-6596-0) | Cabergoline | A-S Medication Solutions | 2023-08-18 |
| 50090-7642-00 | 8 TABLET in 1 BOTTLE (50090-7642-0) | Cabergoline | A-S Medication Solutions | 2025-08-26 |
| 50742-0118-08 | 8 TABLET in 1 BOTTLE (50742-118-08) | Cabergoline | Ingenus Pharmaceuticals, LLC | 2018-08-09 |
| 59762-1005-01 | 8 TABLET in 1 BOTTLE (59762-1005-1) | Cabergoline | Mylan Pharmaceuticals Inc. | 2014-09-22 |
| 64380-0202-01 | 8 TABLET in 1 BOTTLE (64380-202-01) | Cabergoline | Strides Pharma Science Limited | 2024-02-27 |
| 69238-2693-01 | 8 TABLET in 1 BOTTLE (69238-2693-1) | Cabergoline | Amneal Pharmaceuticals NY LLC | 2024-10-03 |
| 70069-0824-08 | 8 TABLET in 1 BOTTLE (70069-824-08) | CABERGOLINE | Somerset Therapeutics, LLC | 2024-10-18 |
| 70512-0860-08 | 8 TABLET in 1 BOTTLE (70512-860-08) | Cabergoline | SOLA Pharmaceuticals, LLC | 2023-05-08 |
Observed labelers:
A-S Medication Solutions (4) ·
Amneal Pharmaceuticals NY LLC (1) ·
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (1) ·
Ingenus Pharmaceuticals, LLC (1) ·
Mylan Pharmaceuticals Inc. (1) ·
SOLA Pharmaceuticals, LLC (1)
· +3 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$1.4462
Range $1.4462–$1.4462
· middle 50% $1.4462–$1.4462
· 7 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J8515 | Cabergoline, oral 0.25mg | 1 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.